Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 17 Ovarian Neoplasms 11 Neoplasms 8 Fallopian Tube Neoplasms 8 Triple Negative Breast Neoplasms 7 Prostatic Neoplasms 6 Neoplasm Metastasis 6 Pancreatic Neoplasms 4 Endometrial Neoplasms 4 Neuroendocrine Tumors 3 Glioma 3 Glioblastoma 3 Carcinoma, Ovarian Epithelial 3 Recurrence 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Fanconi Anemia, Complementation Group D1 2 Cholangiocarcinoma 2 Uveal Melanoma 1 Urogenital Neoplasms 1 Solid Tumors 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma, Synovial 1 SCLC,Extensive Stage 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Platinum-sensitive Ovarian Cancer 1

Interventions

dalpiciclib 2 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pyrotinib 1 pegfilgrastim 1 patritumab deruxtecan 1 olaparib 1 fluzoparib 1 apatinib 1 Ga(III)-DOTATOC 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Breast Cancer Metastatic × olaparib × Clear all

NCT06298084 2024-03-29

ICARUSBREAST02

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡